These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 24126741)
1. Epidermal growth factor enhances androgen receptor‑mediated bladder cancer progression and invasion via potentiation of AR transactivation. Hsieh TF; Chen CC; Ma WL; Chuang WM; Hung XF; Tsai YR; Lin MH; Zhang Q; Zhang C; Chang C; Shyr CR Oncol Rep; 2013 Dec; 30(6):2917-22. PubMed ID: 24126741 [TBL] [Abstract][Full Text] [Related]
2. Promotion of bladder cancer development and progression by androgen receptor signals. Miyamoto H; Yang Z; Chen YT; Ishiguro H; Uemura H; Kubota Y; Nagashima Y; Chang YJ; Hu YC; Tsai MY; Yeh S; Messing EM; Chang C J Natl Cancer Inst; 2007 Apr; 99(7):558-68. PubMed ID: 17406000 [TBL] [Abstract][Full Text] [Related]
3. Dihydrotestosterone interacts with EGFR/MAPK signalling and modulates EGFR levels in androgen receptor-positive LNCaP prostate cancer cells. Mukherjee B; Mayer D Int J Oncol; 2008 Sep; 33(3):623-9. PubMed ID: 18695894 [TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor induces bladder cancer cell proliferation through activation of the androgen receptor. Izumi K; Zheng Y; Li Y; Zaengle J; Miyamoto H Int J Oncol; 2012 Nov; 41(5):1587-92. PubMed ID: 22922989 [TBL] [Abstract][Full Text] [Related]
5. Suppression of ERβ signaling via ERβ knockout or antagonist protects against bladder cancer development. Hsu I; Chuang KL; Slavin S; Da J; Lim WX; Pang ST; O'Brien JH; Yeh S Carcinogenesis; 2014 Mar; 35(3):651-61. PubMed ID: 24148819 [TBL] [Abstract][Full Text] [Related]
6. Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells. Zheng Y; Izumi K; Yao JL; Miyamoto H Endocr Relat Cancer; 2011 Aug; 18(4):451-64. PubMed ID: 21613411 [TBL] [Abstract][Full Text] [Related]
7. Decreased tumorigenesis and mortality from bladder cancer in mice lacking urothelial androgen receptor. Hsu JW; Hsu I; Xu D; Miyamoto H; Liang L; Wu XR; Shyr CR; Chang C Am J Pathol; 2013 May; 182(5):1811-20. PubMed ID: 23499463 [TBL] [Abstract][Full Text] [Related]
8. Increase in amphiregulin and epiregulin in prostate cancer xenograft after androgen deprivation-impact of specific HER1 inhibition. Tørring N; Hansen FD; Sørensen BS; Ørntoft TF; Nexø E Prostate; 2005 Jun; 64(1):1-8. PubMed ID: 15651060 [TBL] [Abstract][Full Text] [Related]
9. Signaling mechanisms that mediate invasion in prostate cancer cells. Bonaccorsi L; Marchiani S; Muratori M; Carloni V; Forti G; Baldi E Ann N Y Acad Sci; 2004 Dec; 1028():283-8. PubMed ID: 15650253 [TBL] [Abstract][Full Text] [Related]
10. The effects of early versus delayed castration targeting androgen on prolonging survival in a mouse model of bladder cancer. Zhang Z; Xu Q; Huang X; Yang J; Xu Y; Zhang G Int J Clin Exp Pathol; 2015; 8(9):10283-93. PubMed ID: 26617736 [TBL] [Abstract][Full Text] [Related]
11. Long-term presence of androgens and anti-androgens modulate EGF-receptor expression and MAP-kinase phosphorylation in androgen receptor-prostate positive cancer cells. Gravina GL; Festuccia C; Angelucci A; Poletti A; Capuano D; Vicentini C; Motta M; Bologna M Int J Oncol; 2004 Jul; 25(1):97-104. PubMed ID: 15201994 [TBL] [Abstract][Full Text] [Related]
12. An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines. Paliouras M; Diamandis EP Biol Chem; 2008 Jun; 389(6):773-80. PubMed ID: 18627304 [TBL] [Abstract][Full Text] [Related]
13. Targeting androgen receptor (AR) with antiandrogen Enzalutamide increases prostate cancer cell invasion yet decreases bladder cancer cell invasion via differentially altering the AR/circRNA-ARC1/miR-125b-2-3p or miR-4736/PPARγ/MMP-9 signals. Deng G; Wang R; Sun Y; Huang CP; Yeh S; You B; Feng C; Li G; Ma S; Chang C Cell Death Differ; 2021 Jul; 28(7):2145-2159. PubMed ID: 34127806 [TBL] [Abstract][Full Text] [Related]
14. Crosstalk between androgen receptor and epidermal growth factor receptor-signalling pathways: a molecular switch for epithelial cell differentiation. Léotoing L; Manin M; Monté D; Baron S; Communal Y; Lours C; Veyssière G; Morel L; Beaudoin C J Mol Endocrinol; 2007 Aug; 39(2):151-62. PubMed ID: 17693613 [TBL] [Abstract][Full Text] [Related]
15. The androgen receptor and prostate cancer invasion. Bonaccorsi L; Muratori M; Marchiani S; Forti G; Baldi E Mol Cell Endocrinol; 2006 Feb; 246(1-2):157-62. PubMed ID: 16376012 [TBL] [Abstract][Full Text] [Related]
16. A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells. Recchia AG; Musti AM; Lanzino M; Panno ML; Turano E; Zumpano R; Belfiore A; Andò S; Maggiolini M Int J Biochem Cell Biol; 2009 Mar; 41(3):603-14. PubMed ID: 18692155 [TBL] [Abstract][Full Text] [Related]
17. EGF receptor (EGFR) signaling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR). Bonaccorsi L; Carloni V; Muratori M; Formigli L; Zecchi S; Forti G; Baldi E Int J Cancer; 2004 Oct; 112(1):78-86. PubMed ID: 15305378 [TBL] [Abstract][Full Text] [Related]
18. Effect of type I growth factor receptor tyrosine kinase inhibitors on phosphorylation and transactivation activity of the androgen receptor in prostate cancer cells: Ligand-independent activation of the N-terminal domain of the androgen receptor. Sugita S; Kawashima H; Tanaka T; Kurisu T; Sugimura K; Nakatani T Oncol Rep; 2004 Jun; 11(6):1273-9. PubMed ID: 15138566 [TBL] [Abstract][Full Text] [Related]
19. Tumor microenvironment B cells increase bladder cancer metastasis via modulation of the IL-8/androgen receptor (AR)/MMPs signals. Ou Z; Wang Y; Liu L; Li L; Yeh S; Qi L; Chang C Oncotarget; 2015 Sep; 6(28):26065-78. PubMed ID: 26305549 [TBL] [Abstract][Full Text] [Related]
20. Conditional Expression of the Androgen Receptor Increases Susceptibility of Bladder Cancer in Mice. Johnson DT; Hooker E; Luong R; Yu EJ; He Y; Gonzalgo ML; Sun Z PLoS One; 2016; 11(2):e0148851. PubMed ID: 26862755 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]